Patients referred to the NIH for new, recurrent, and/or metastatic paraganglioma or pheochromocytoma were confirmed for EPAS1 gain-of-function mutation; imaging was evaluated for vascular malformations. This evidence concerns the gene EPAS1 and hereditary pheochromocytoma-paraganglioma.